Vaccine Antigen Master Files: Certifying the Antigen Once and Using It Across Products

A veterinary vaccine antigen master file (VAMF) lets you put the quality data for one antigen in a stand-alone file, have it assessed centrally by EMA, and reuse the resulting certificate across several vaccines and marketing authorisations.

What a VAMF is

A VAMF is a stand-alone part of a vaccine marketing authorisation dossier. It holds the quality information for a single antigen or active substance, and the same file can support several monovalent or combined vaccines from one applicant or marketing authorisation holder. Use of the system is optional. For a combined vaccine, a separate VAMF is needed for each antigen the applicant chooses to handle this way.

Legal basis and guidance

The concept comes from Regulation (EU) 2019/6, with the requirements set out in Annex II, as replaced by Commission Delegated Regulation (EU) 2021/805. EMA has published procedural advice on VAMF certification and a CVMP guideline on the data requirements, which should be read together before planning a submission.

Two routes to certification

  • With a new centralised application: the VAMF is submitted alongside a vaccine MAA containing a new antigen, a novel antigen combination or a new formulation. It is assessed on the MAA timetable and certified at the CVMP opinion stage.
  • For an existing antigen: a marketing authorisation holder can submit a VAMF for an antigen already in vaccines authorised through the centralised, decentralised or mutual recognition routes. EMA’s procedural advice describes a defined assessment timetable with a clock stop if questions are raised.

In both cases EMA issues a certificate of compliance with Union legislation, and the competent authority then takes the certificate into account when granting or maintaining the authorisation of the affected products.

Planning points

  • Declare your intention early. The procedural advice expects notification several months before submission, so the VAMF decision belongs in the regulatory strategy, not in the final weeks of dossier assembly.
  • Decide which antigens genuinely benefit. A VAMF pays off where one antigen is shared across several products or sites; for a single product it may add little.
  • Plan the lifecycle. Once certified, the certificate has to be introduced into the linked authorisations by variation, and later changes to the antigen data need to be managed consistently across every product that relies on it.

Common pitfalls

Teams most often underestimate the coordination burden: the VAMF holder and the finished-product holders must agree who owns changes, how they are communicated, and how the certificate is kept aligned with each product dossier. A clear technical agreement avoids divergence between the file and the products it supports.

Related reading

How PQRA helps

PQRA advises veterinary vaccine developers and marketing authorisation holders on dossier strategy, deciding whether a VAMF fits a product portfolio, preparing the quality documentation, and coordinating the variations needed to link a certificate to each authorisation.

Ready to talk it through? Contact the PQRA team.

CATEGORIES:

Uncategorized

Tags:

No responses yet

Αφήστε μια απάντηση

Η ηλ. διεύθυνση σας δεν δημοσιεύεται. Τα υποχρεωτικά πεδία σημειώνονται με *